THE PREVENTION OF BREAST CANCER

The Lancet

Volumn 327, Issue 8472, 1986, Pages 83-86

  Cuzick, J ^a   Wang, D Y ^a   Bulbrook, R D ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

BREAST; BREAST CANCER; EPIDEMIOLOGY; HUMAN; PREVENTION; PRIORITY JOURNAL; THERAPY; UNITED KINGDOM;

ADULT; AGED; BREAST NEOPLASMS; CLINICAL TRIALS; FEMALE; FIBROCYSTIC DISEASE OF BREAST; HUMAN; MAMMOGRAPHY; MASS SCREENING; MATERNAL AGE; MENOPAUSE; MIDDLE AGE; PARITY; SEX HORMONE-BINDING GLOBULIN; TAMOXIFEN;

EID: 0022635855     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(86)90729-4     Document Type: Article

References (44)

1. L-Phenylalanine mustard (L-Pam) in the management of primary breast cancer: a report of early findings
2. Combination chemotherapy as an adjuvant treatment in operable breast cancer
3. Adjuvant CMF chemotherapy in operable breast cancer: Ten years later
4. Controlled trial oftamoxifen as single adjuvant agent in management of early breast cancer
5. Review of mortality results in randomised trials in early breast cancer
6. Periodic breast cancer screening in reducing mortality from breast cancer
7. Ten-to-fourteen year effect of screening on breast cancer mortality
8. Reduction of breast cancer mortality through mass screening with modern mammography: first results of the Nijmegen project 1975-1981
9. Evaluation of screening for breast cancer in a non-randomised study (the DOM project) by means of a case-control study
10. Reduction in mortality from breast cancer after mass screening with mammography
11. Trends in the incidence of cervical cancer in Nordic countries
12. Hormones and neoplasia
13. Tamoxifen: A review of its pharmacological properties and therapeutic use in treatment of breast cancer
14. Study of epidemiology of cancer of the breast influence of hysterectomy
15. Breast cancer in relation to nursing and menopausal history
16. A review of the epidemiology of human breast cancer
17. Serum concentration oftotal and non-protein-bound oestradiol in patients with breast cancer and in normal controls
18. Plasma levels of estrone, estrone sulfate and estriol and percentage of unbound estradiol in postmenopausal women with and without breast cancer
19. Elevated percentage of non-protein bound estradiol (E2) in early breast cancer
20. Serum binding of oestradiol in normal women and women with breast disease
21. Increased availability of serum estrogens in breast cancer. a new hypothesis
22. The serum transport of steroid hormones
23. Distribution of 17β-estradiol in the sera of normal British and Japanese women
24. Is hormonal responsiveness in breast cancer age dependent?
25. Tamoxifen and contralateral breast cancer
26. Increases in steroid binding globulins induced by tamoxifen in patients with carcinoma of the breast
27. The pharmacology and clinical uses of tamoxifen
28. Adjuvant tamoxifen for operable carcinoma of the breast: Report of clinical trial by the Christie Hospital and Holt Radium Institute
29. Venous thrombosis as a side effect of tamoxifen treatment
30. Increased incidence of thrombo-embolism in stage IV breast cancer patients treated with a five-drug chemotherapy regimen
31. The effect of tamoxifen on bone mineral content in premenopausal women with breast cancer
32. Serum lipoproteins and proteins after breast cancer surgery and effects of tamoxifen
33. Tamoxifen
34. Tamoxifen-induced hypercalcemia in breast cancer
35. Tamoxifen and liver damage
36. Tamoxifen retinopathy
37. Etiology of human breast cancer: A review
38. Risk of familial breast cancer
39. Epidemiology and endocrinology of benign breast disease
40. Risk factors for breast cancer in women with proliferative breast disease
41. Risk for breast cancer development determined by mammographic parenchymal pattern
42. Mammographic patterns and breast cancer risk: Methodologic standards and contradictory results